An observational study in Schizophrenia, sponsored by Janssen Korea, Ltd., Korea. Completed at 1 site in Korea, Republic of. Per ClinicalTrials.gov, last updated 2025-04-27.
Sponsored by Janssen Korea, Ltd., Korea · Observational
The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.
This is an open-label (all people know the identity of the intervention), multi-center, prospective (look forward using observations collected following participant enrollment), non-comparative, non-randomized (the study medication is not assigned by chance), study. Safety and efficacy of paliperidone palmitate will be observed in Korean schizophrenic participants for 25 weeks. Approximately 3000 participants will be observed in this study and the study duration will be 25 weeks. Safety evaluations will include assessment of adverse events, concomitant medications, physical examination, and psychiatric history.
3,471 studies on the registry are indexed under Schizophrenia; 471 are open to participants now.
This study's enrollment of 3,267 is above the median of 178 across 491 observational studies indexed under Schizophrenia.
Browse Schizophrenia studies →Janssen Korea, Ltd., Korea is the lead sponsor of 75 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants with schizophrenia and prescribed with paliperidone palmitate for acute or maintenance treatment.
Exclusion Criteria:
Drug: No intervention
This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
Number of participants with adverse events up to Week 9
Time frame: Up to Week 9
Number of participants with adverse events up to Week 25
Time frame: Up to Week 25
Change from baseline in Clinical Global impression-Severity (CGI-S) scale scores
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.
Time frame: Baseline (Day 1), Week 5, Week 9, Week 13, Week 17, Week 21, and Week 25
Change from baseline in Personal and Social Performance (PSP) scale scores
This PSP assesses the degree of a participants dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (i, absent to vi, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; =\< 30, functioning so poorly as to require intensive supervision.
Time frame: Baseline (Day 1), Week 5, Week 9, Week 13, Week 17, Week 21, and Week 25
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Korea, Ltd., Korea